The Isolator® Synergy™ clamps deliver durable lesions for patients with persistent and long-standing persistent Afib.​

In the multicenter ABLATE PAS study, freedom from Afib at 3 years was 76% and 64% on and off antiarrhythmic meds respectively, with no device-related complications.​

Proven technology. Durable outcomes. Transformed lives. ​

Learn more about the ABLATE PAS study at <a href='https://www.linkedin.com/feed/hashtag/?keywords=AATS2026&highlightedUpd…; target='_blank'>#AATS2026</a> or by visiting <a href="https://okt.to/6WNDPh&quot; target="_blank">https://okt.to/6WNDPh</a&gt;